Recent studies and case reports, however, postulate FAP-positive PET/CT in PSMA negative/FDG positive disease, underlining the relevance of FAP-based imaging only in late stages and clinical aggressive tumors of the prostate [7, 26, 27]. Here, FOLH1 is linked to prostate neoplasm.